Stock Comparison

CNTB vs UNH

Connect Biopharma Holdings Ltd vs UnitedHealth Group Inc

The Verdict

CNTB takes this one.

Winner

CNTB

Connect Biopharma Holdings Ltd

4.3

out of 10

Proceed with Caution

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Head-to-Head

$157M

Market Cap

$276.2B

-3.8

P/E Ratio

22.9

0.0%

Profit Margin

2.7%

-59.7%

Return on Equity

12.5%

0.0

Debt-to-Equity

0.0

Aggressive

Overall Risk

Moderate-High

4.3

DVR Score

0.3

The Deep Dive

CNTB4.3/10

Connect Biopharma (CNTB) remains a high-risk, high-reward biotech play with potential for significant upside if its lead pipeline asset, Rademikibart, successfully navigates clinical trials. The company targets large immunology markets (asthma, COPD, atopic dermatitis), and recent pipeline execution includes a China NDA submission for Rademikibart. Financial health shows excellent liquidity ratios...

Full CNTB Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.